Marfan Syndrome (MFS): Inherited Microfibrillar Disorder Caused by Mutations in the Fibrillin-1 Gene

  • Jose Antonio Aragon-Martin
  • Anne H. Child


There have been several studies suggesting that FBN1 gene was responsible for the Marfan syndrome (MFS) phenotype [1–4] before announcing the localisation of the gene on chromosome 15q21.1 in 1991 [3, 5, 6]. Subsequently, many research laboratories started to screen FBN1 in their MFS patients. Many mutations have been mapped to this gene due to this increase in genetic screening and international collaborations confirming FBN1 as the gene responsible for Marfan syndrome [7–15]. This has been the final proof to confirm that the FBN1 gene is the cause of MFS.


Autosomal dominant inheritance Calcium binding epidermal growth factor-like (cbEGF-like) domains Cysteine Deletions dHPLC analysis Disulphide bonds Duplications Ectopia Lentis (EL) Exons Fibrillin-1 (FBN1) gene Genomic DNA Genotype-phenotype association Haploinsufficiency Incidence Introns Life expectancy Microfibrillar Mitral valve Aorta Skeleton Skin syndrome (MASS) MLPA technique Modifiers Mutation screening Neonatal region Next generation sequencing (NGS) Non-synonymous causative variations Non-synonymous variants Nucleotide sequence Overlapping syndromes Promoter Sanger sequencing Spliceosome Spontaneous mutation Thoracic Aortic Aneurysm and Dissection (TAAD) Transforming growth factor-β binding protein-like (TGFBP) Universal mutation database (UMD) Whole genome/exome sequencing 


  1. 1.
    Sakai LY, Keene DR, Engvall E. Fibrillin, a new 350-kD glycoprotein, is a component of extracellular microfibrils. J Cell Biol. 1986;103(6 Pt 1):2499–509.CrossRefPubMedGoogle Scholar
  2. 2.
    Hollister DW, Godfrey M, Sakai LY, Pyeritz RE. Immunohistologic abnormalities of the microfibrillar-fiber system in the Marfan syndrome. N Engl J Med. 1990;323(3):152–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Dietz HC, Pyeritz RE, Hall BD, Cadle RG, Hamosh A, Schwartz J, Meyers DA, Francomano CA. The Marfan syndrome locus: confirmation of assignment to chromosome 15 and identification of tightly linked markers at 15q15-q21.3. Genomics. 1991;9(2):355–61.CrossRefPubMedGoogle Scholar
  4. 4.
    Kainulainen K, Pulkkinen L, Savolainen A, Kaitila I, Peltonen L. Location on chromosome 15 of the gene defect causing Marfan syndrome. N Engl J Med. 1990;323(14):935–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Magenis RE, Maslen CL, Smith L, Allen L, Sakai LY. Localization of the fibrillin (FBN) gene to chromosome 15, band q21.1. Genomics. 1991;11(2):346–51.CrossRefPubMedGoogle Scholar
  6. 6.
    Lee B, Godfrey M, Vitale E, Hori H, Mattei MG, Sarfarazi M, Tsipouras P, Ramirez F, Hollister DW. Linkage of Marfan syndrome and a phenotypically related disorder to two different fibrillin genes. Nature. 1991;352(6333):330–4.CrossRefPubMedGoogle Scholar
  7. 7.
    Comeglio P, Johnson P, Arno G, Brice G, Evans A, Aragon-Martin J, da Silva FP, Kiotsekoglou A, Child A. The importance of mutation detection in Marfan syndrome and Marfan-related disorders: report of 193 FBN1 mutations. Hum Mutat. 2007;28(9):928–50.Google Scholar
  8. 8.
    Collod-Béroud G, Lackmy-Port-Lys M, Jondeau G, Mathieu M, Maingourd Y, Coulon M, Guillotel M, Junien C, Boileau C. Demonstration of the recurrence of Marfan-like skeletal and cardiovascular manifestations due to germline mosaicism for an FBN1 mutation. Am J Hum Genet. 1999;65(3):917–21.CrossRefPubMedCentralPubMedGoogle Scholar
  9. 9.
    Blyth M, Foulds N, Turner C, Bunyan D. Severe Marfan syndrome due to FBN1 exon deletions. Am J Med Genet A. 2008;146A(10):1320–4.CrossRefPubMedGoogle Scholar
  10. 10.
    Montgomery RA, Geraghty MT, Bull E, Gelb BD, Johnson M, McIntosh I, Francomano CA, Dietz HC. Multiple molecular mechanisms underlying subdiagnostic variants of Marfan syndrome. Am J Hum Genet. 1998;63(6):1703–11.CrossRefPubMedCentralPubMedGoogle Scholar
  11. 11.
    Hayward C, Porteous ME, Brock DJ. Mutation screening of all 65 exons of the fibrillin-1 gene in 60 patients with Marfan syndrome: report of 12 novel mutations. Hum Mutat. 1997;10(4):280–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Hayward C, Keston M, Brock DJ, Dietz HC. Fibrillin (FBN1) mutations in Marfan syndrome. Hum Mutat. 1992;1(1):79.CrossRefPubMedGoogle Scholar
  13. 13.
    Dietz HC, Cutting GR, Pyeritz RE, Maslen CL, Sakai LY, Corson GM, Puffenberger EG, Hamosh A, Nanthakumar EJ, Curristin SM. Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature. 1991;352(6333):337–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Dietz HC, McIntosh I, Sakai LY, Corson GM, Chalberg SC, Pyeritz RE, Francomano CA. Four novel FBN1 mutations: significance for mutant transcript level and EGF-like domain calcium binding in the pathogenesis of Marfan syndrome. Genomics. 1993;17(2):468–75.CrossRefPubMedGoogle Scholar
  15. 15.
    Tynan K, Comeau K, Pearson M, Wilgenbus P, Levitt D, Gasner C, Berg MA, Miller DC, Francke U. Mutation screening of complete fibrillin-1 coding sequence: report of five new mutations, including two in 8-cysteine domains. Hum Mol Genet. 1993;2(11):1813–21.CrossRefPubMedGoogle Scholar
  16. 16.
    McKUSICK VA. The cardiovascular aspects of Marfan’s syndrome: a heritable disorder of connective tissue. Circulation. 1955;11(3):321–42.CrossRefPubMedGoogle Scholar
  17. 17.
    de Vries BB, Pals G, Odink R, Hamel BC. Homozygosity for a FBN1 missense mutation: clinical and molecular evidence for recessive Marfan syndrome. Eur J Hum Genet. 2007;15(9):930–5.CrossRefPubMedGoogle Scholar
  18. 18.
    Hogue J, Lee C, Jelin A, Strecker MN, Cox VA, Slavotinek AM. Homozygosity for a FBN1 missense mutation causes a severe Marfan syndrome phenotype. Clin Genet. 2013;84(4):392–3.CrossRefPubMedGoogle Scholar
  19. 19.
    Capotorti L, de Benedetti Gaddini R, Rizzo P. Contribution to the study of the heredity of Marfan’s syndrome: description of a family tree of 4 generations with marriage between consanguineous parents. Acta Genet Med Gemellol (Roma). 1959;8:455–82.Google Scholar
  20. 20.
    Chemke J, Nisani R, Feigl A, Garty R, Cooper M, Bårash Y, Duksin D. Homozygosity for autosomal dominant Marfan syndrome. J Med Genet. 1984;21(3):173–7.CrossRefPubMedCentralPubMedGoogle Scholar
  21. 21.
    Schollin J, Bjarke B, Gustavson KH. Probable homozygotic form of the Marfan syndrome in a newborn child. Acta Paediatr Scand. 1988;77(3):452–6.CrossRefPubMedGoogle Scholar
  22. 22.
    Karttunen L, Raghunath M, Lönnqvist L, Peltonen L. A compound-heterozygous Marfan patient: two defective fibrillin alleles result in a lethal phenotype. Am J Hum Genet. 1994;55(6):1083–91.PubMedCentralPubMedGoogle Scholar
  23. 23.
    Van Dijk FS, Hamel BC, Hilhorst-Hofstee Y, Mulder BJ, Timmermans J, Pals G, Cobben JM. Compound-heterozygous Marfan syndrome. Eur J Med Genet. 2009;52(1):1–5.CrossRefPubMedGoogle Scholar
  24. 24.
    Keane MG, Pyeritz RE. Medical management of Marfan syndrome. Circulation. 2008;117(21):2802–13.CrossRefPubMedGoogle Scholar
  25. 25.
    Judge DP, Dietz HC. Marfan’s syndrome. Lancet. 2005;366(9501):1965–76.CrossRefPubMedCentralPubMedGoogle Scholar
  26. 26.
    Chiu HH, Wu MH, Chen HC, Kao FY, Huang SK. Epidemiological profile of Marfan syndrome in a general population: a national database study. Mayo Clin Proc. 2014;89(1):34–42.CrossRefPubMedGoogle Scholar
  27. 27.
    Dean JC. Management of Marfan syndrome. Heart. 2002;88(1):97–103.CrossRefPubMedCentralPubMedGoogle Scholar
  28. 28.
    Silverman DI, Burton KJ, Gray J, Bosner MS, Kouchoukos NT, Roman MJ, Boxer M, Devereux RB, Tsipouras P. Life expectancy in the Marfan syndrome. Am J Cardiol. 1995;75(2):157–60.CrossRefPubMedGoogle Scholar
  29. 29.
    Pyeritz RE. Marfan syndrome: 30 years of research equals 30 years of additional life expectancy. Heart. 2009;95(3):173–5.CrossRefPubMedGoogle Scholar
  30. 30.
    Corson GM, Chalberg SC, Dietz HC, Charbonneau NL, Sakai LY. Fibrillin binds calcium and is coded by cDNAs that reveal a multidomain structure and alternatively spliced exons at the 5’ end. Genomics. 1993;17(2):476–84.CrossRefPubMedGoogle Scholar
  31. 31.
    Pereira L, D’Alessio M, Ramirez F, Lynch JR, Sykes B, Pangilinan T, Bonadio J. Genomic organization of the sequence coding for fibrillin, the defective gene product in Marfan syndrome. Hum Mol Genet. 1993;2(7):961–8.CrossRefPubMedGoogle Scholar
  32. 32.
    Summers KM, Nataatmadja M, Xu D, West MJ, McGill JJ, Whight C, Colley A, Adès LC. Histopathology and fibrillin-1 distribution in severe early onset Marfan syndrome. Am J Med Genet A. 2005;139(1):2–8.CrossRefPubMedGoogle Scholar
  33. 33.
    Milewicz DM, Pyeritz RE, Crawford ES, Byers PH. Marfan syndrome: defective synthesis, secretion, and extracellular matrix formation of fibrillin by cultured dermal fibroblasts. J Clin Invest. 1992;89(1):79–86.CrossRefPubMedCentralPubMedGoogle Scholar
  34. 34.
    Raghunath M, Kielty CM, Steinmann B. Truncated profibrillin of a Marfan patient is of apparent similar size as fibrillin: intracellular retention leads to over-N-glycosylation. J Mol Biol. 1995;248(5):901–9.CrossRefPubMedGoogle Scholar
  35. 35.
    Kainulainen K, Karttunen L, Puhakka L, Sakai L, Peltonen L. Mutations in the fibrillin gene responsible for dominant ectopia lentis and neonatal Marfan syndrome. Nat Genet. 1994;6(1):64–9.CrossRefPubMedGoogle Scholar
  36. 36.
    Milewicz DM, Duvic M. Severe neonatal Marfan syndrome resulting from a de novo 3-bp insertion into the fibrillin gene on chromosome 15. Am J Hum Genet. 1994;54(3):447–53.PubMedCentralPubMedGoogle Scholar
  37. 37.
    Putnam EA, Cho M, Zinn AB, Towbin JA, Byers PH, Milewicz DM. Delineation of the Marfan phenotype associated with mutations in exons 23–32 of the FBN1 gene. Am J Med Genet. 1996;62(3):233–42.CrossRefPubMedGoogle Scholar
  38. 38.
    Sakai LY, Keene DR. Fibrillin: monomers and microfibrils. Methods Enzymol. 1994;245:29–52.CrossRefPubMedGoogle Scholar
  39. 39.
    Biery NJ, Eldadah ZA, Moore CS, Stetten G, Spencer F, Dietz HC. Revised genomic organization of FBN1 and significance for regulated gene expression. Genomics. 1999;56(1):70–7.CrossRefPubMedGoogle Scholar
  40. 40.
    Collod-Béroud G, Le Bourdelles S, Ades L, Ala-Kokko L, Booms P, Boxer M, Child A, Comeglio P, De Paepe A, Hyland JC. and others. Update of the UMD-FBN1 mutation database and creation of an FBN1 polymorphism database. Hum Mutat. 2003;22(3):199–208.CrossRefPubMedGoogle Scholar
  41. 41.
    Dietz HC, Saraiva JM, Pyeritz RE, Cutting GR, Francomano CA. Clustering of fibrillin (FBN1) missense mutations in Marfan syndrome patients at cysteine residues in EGF-like domains. Hum Mutat. 1992;1(5):366–74.CrossRefPubMedGoogle Scholar
  42. 42.
    Smallridge RS, Whiteman P, Doering K, Handford PA, Downing AK. EGF-like domain calcium affinity modulated by N-terminal domain linkage in human fibrillin-1. J Mol Biol. 1999;286(3):661–8.CrossRefPubMedGoogle Scholar
  43. 43.
    Kielty CM, Rantamäki T, Child AH, Shuttleworth CA, Peltonen L. Cysteine-to-arginine point mutation in a ‘hybrid’ eight-cysteine domain of FBN1: consequences for fibrillin aggregation and microfibril assembly. J Cell Sci. 1995;108(Pt 3):1317–23.PubMedGoogle Scholar
  44. 44.
    Micheal S, Khan MI, Akhtar F, Weiss MM, Islam F, Ali M, Qamar R, Maugeri A, den Hollander AI. Identification of a novel FBN1 gene mutation in a large Pakistani family with Marfan syndrome. Mol Vis. 2012;18:1918–26.PubMedCentralPubMedGoogle Scholar
  45. 45.
    Collod-Béroud G, Béroud C, Ades L, Black C, Boxer M, Brock DJ, Holman KJ, de Paepe A, Francke U, Grau U. Marfan Database (third edition): new mutations and new routines for the software. Nucleic Acids Res. 1998;26(1):229–33.CrossRefPubMedCentralPubMedGoogle Scholar
  46. 46.
    Liu WO, Oefner PJ, Qian C, Odom RS, Francke U. Denaturing HPLC-identified novel FBN1 mutations, polymorphisms, and sequence variants in Marfan syndrome and related connective tissue disorders. Genet Test. 1997;1(4):237–42.CrossRefPubMedGoogle Scholar
  47. 47.
    Lönnqvist L, Child A, Kainulainen K, Davidson R, Puhakka L, Peltonen L. A novel mutation of the fibrillin gene causing ectopia lentis. Genomics. 1994;19(3):573–6.CrossRefPubMedGoogle Scholar
  48. 48.
    Reinhardt DP, Mechling DE, Boswell BA, Keene DR, Sakai LY, Bächinger HP. Calcium determines the shape of fibrillin. J Biol Chem. 1997;272(11):7368–73.CrossRefPubMedGoogle Scholar
  49. 49.
    Reinhardt DP, Ono RN, Sakai LY. Calcium stabilizes fibrillin-1 against proteolytic degradation. J Biol Chem. 1997;272(2):1231–6.CrossRefPubMedGoogle Scholar
  50. 50.
    Reinhardt DP, Ono RN, Notbohm H, Müller PK, Bächinger HP, Sakai LY. Mutations in calcium-binding epidermal growth factor modules render fibrillin-1 susceptible to proteolysis. A potential disease-causing mechanism in Marfan syndrome. J Biol Chem. 2000;275(16):12339–45.CrossRefPubMedGoogle Scholar
  51. 51.
    Ashworth JL, Murphy G, Rock MJ, Sherratt MJ, Shapiro SD, Shuttleworth CA, Kielty CM. Fibrillin degradation by matrix metalloproteinases: implications for connective tissue remodelling. Biochem J. 1999;340(Pt 1):171–81.CrossRefPubMedCentralPubMedGoogle Scholar
  52. 52.
    McGettrick AJ, Knott V, Willis A, Handford PA. Molecular effects of calcium binding mutations in Marfan syndrome depend on domain context. Hum Mol Genet. 2000;9(13):1987–94.CrossRefPubMedGoogle Scholar
  53. 53.
    Loeys B, Nuytinck L, Van Acker P, Walraedt S, Bonduelle M, Sermon K, Hamel B, Sanchez A, Messiaen L, De Paepe A. Strategies for prenatal and preimplantation genetic diagnosis in Marfan syndrome (MFS). Prenat Diagn. 2002;22(1):22–8.CrossRefPubMedGoogle Scholar
  54. 54.
    Schrijver I, Liu W, Brenn T, Furthmayr H, Francke U. Cysteine substitutions in epidermal growth factor-like domains of fibrillin-1: distinct effects on biochemical and clinical phenotypes. Am J Hum Genet. 1999;65(4):1007–20.CrossRefPubMedCentralPubMedGoogle Scholar
  55. 55.
    Gillis E, Kempers M, Salemink S, Timmermans J, Cheriex EC, Bekkers SC, Fransen E, De Die-Smulders CE, Loeys BL, Van Laer L. An FBN1 deep intronic mutation in a familial case of Marfan syndrome: an explanation for genetically unsolved cases? Hum Mutat. 2014;35(5):571–4.CrossRefPubMedGoogle Scholar
  56. 56.
    Dietz HC, Valle D, Francomano CA, Kendzior RJ, Pyeritz RE, Cutting GR. The skipping of constitutive exons in vivo induced by nonsense mutations. Science. 1993;259(5095):680–3.CrossRefPubMedGoogle Scholar
  57. 57.
    Kainulainen K, Sakai LY, Child A, Pope FM, Puhakka L, Ryhänen L, Palotie A, Kaitila I, Peltonen L. Two mutations in Marfan syndrome resulting in truncated fibrillin polypeptides. Proc Natl Acad Sci U S A. 1992;89(13):5917–21.CrossRefPubMedCentralPubMedGoogle Scholar
  58. 58.
    Körkkö J, Kaitila I, Lönnqvist L, Peltonen L, Ala-Kokko L. Sensitivity of conformation sensitive gel electrophoresis in detecting mutations in Marfan syndrome and related conditions. J Med Genet. 2002;39(1):34–41.CrossRefPubMedCentralPubMedGoogle Scholar
  59. 59.
    Franken R, den Hartog A, Radonic T, Micha D, Maugeri A, van Dijk FS, Meijers-Heijboer HE, Timmermans J, Scholte AJ, van den Berg MP. Beneficial Outcome of Losartan Therapy Depends on Type of FBN1 Mutation in Marfan Syndrome. Circ Cardiovasc Genet. 2015;8(2):383–8.CrossRefPubMedGoogle Scholar
  60. 60.
    Franken R, Heesterbeek T, de Waard V, Zwinderman A, Pals G, Mulder B, Groenink M. Diagnosis and genetics of Marfan syndrome. Expert Opinion Orphan Drugs. 2014;2(10):1049–62.CrossRefGoogle Scholar
  61. 61.
    Attias D, Stheneur C, Roy C, Collod-Béroud G, Detaint D, Faivre L, Delrue MA, Cohen L, Francannet C, Béroud C. and others. Comparison of clinical presentations and outcomes between patients with TGFBR2 and FBN1 mutations in Marfan syndrome and related disorders. Circulation. 2009;120(25):2541–9.CrossRefPubMedGoogle Scholar
  62. 62.
    Hilhorst-Hofstee Y, Hamel BC, Verheij JB, Rijlaarsdam ME, Mancini GM, Cobben JM, Giroth C, Ruivenkamp CA, Hansson KB, Timmermans J. and others. The clinical spectrum of complete FBN1 allele deletions. Eur J Hum Genet. 2011;19(3):247–52.CrossRefPubMedCentralPubMedGoogle Scholar
  63. 63.
    Nijbroek G, Sood S, McIntosh I, Francomano CA, Bull E, Pereira L, Ramirez F, Pyeritz RE, Dietz HC. Fifteen novel FBN1 mutations causing Marfan syndrome detected by heteroduplex analysis of genomic amplicons. Am J Hum Genet. 1995;57(1):8–21.PubMedCentralPubMedGoogle Scholar
  64. 64.
    McInerney-Leo AM, Marshall MS, Gardiner B, Coucke PJ, Van Laer L, Loeys BL, Summers KM, Symoens S, West JA, West MJ. Whole exome sequencing is an efficient, sensitive and specific method of mutation detection in osteogenesis imperfecta and Marfan syndrome. Bonekey Rep. 2013;2:456.CrossRefPubMedCentralPubMedGoogle Scholar
  65. 65.
    Bayley H. Sequencing single molecules of DNA. Curr Opin Chem Biol. 2006;10(6):628–37.CrossRefPubMedGoogle Scholar
  66. 66.
    Schneider GF, Dekker C. DNA sequencing with nanopores. Nat Biotechnol. 2012;30(4):326–8.CrossRefPubMedGoogle Scholar
  67. 67.
    Wang Y, Yang Q, Wang Z. The evolution of nanopore sequencing. Front Genet. 2014;5:449.PubMedCentralPubMedGoogle Scholar
  68. 68.
    Boileau C, Jondeau G, Babron MC, Coulon M, Alexandre JA, Sakai L, Melki J, Delorme G, Dubourg O, Bonaïti-Pellié C. Autosomal dominant Marfan-like connective-tissue disorder with aortic dilation and skeletal anomalies not linked to the fibrillin genes. Am J Hum Genet. 1993;53(1):46–54.PubMedCentralPubMedGoogle Scholar

Copyright information

© Springer-Verlag London 2016

Authors and Affiliations

  1. 1.Sonalee Laboratory, Cardiovascular and Cell Sciences Research InstituteSt George’s, University of LondonLondonUK
  2. 2.Cardiovascular and Cell Sciences Research InstituteSt George’s, University of LondonLondonUK

Personalised recommendations